Neurocrine Biosciences (NBIX) Lowered to “Sell” at BidaskClub
Neurocrine Biosciences (NASDAQ:NBIX) was downgraded by investment analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued on Friday.
Several other research analysts have also issued reports on the company. Oppenheimer set a $140.00 target price on Neurocrine Biosciences and gave the company a “buy” rating in a research report on Wednesday, September 12th. Needham & Company LLC set a $125.00 target price on Neurocrine Biosciences and gave the company a “buy” rating in a research report on Wednesday, August 1st. HC Wainwright restated a “buy” rating and set a $162.00 target price on shares of Neurocrine Biosciences in a research report on Wednesday, August 1st. Jefferies Financial Group boosted their target price on Neurocrine Biosciences to $124.00 and gave the company a “buy” rating in a research report on Monday, July 30th. Finally, Stifel Nicolaus began coverage on Neurocrine Biosciences in a research report on Tuesday, August 7th. They set a “buy” rating and a $137.00 target price for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and sixteen have given a buy rating to the company. Neurocrine Biosciences has a consensus rating of “Buy” and a consensus target price of $125.75.
Shares of NASDAQ NBIX opened at $91.71 on Friday. Neurocrine Biosciences has a 1-year low of $67.32 and a 1-year high of $126.98. The company has a market cap of $9.34 billion, a price-to-earnings ratio of -56.61, a P/E/G ratio of 28.25 and a beta of 0.94.
In related news, Director Richard F. Pops sold 5,500 shares of the business’s stock in a transaction that occurred on Monday, October 29th. The stock was sold at an average price of $107.13, for a total value of $589,215.00. Following the completion of the sale, the director now owns 37,759 shares in the company, valued at $4,045,121.67. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gary A. Lyons sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, November 2nd. The shares were sold at an average price of $114.41, for a total value of $1,716,150.00. The disclosure for this sale can be found here. Insiders sold 33,623 shares of company stock valued at $3,721,361 in the last quarter. 4.30% of the stock is owned by company insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Meeder Asset Management Inc. boosted its holdings in shares of Neurocrine Biosciences by 643.7% in the second quarter. Meeder Asset Management Inc. now owns 1,123 shares of the company’s stock valued at $110,000 after purchasing an additional 972 shares during the period. TRUE Private Wealth Advisors purchased a new stake in shares of Neurocrine Biosciences in the third quarter valued at approximately $127,000. Steward Partners Investment Advisory LLC purchased a new stake in shares of Neurocrine Biosciences in the third quarter valued at approximately $127,000. Signaturefd LLC boosted its holdings in shares of Neurocrine Biosciences by 295.9% in the third quarter. Signaturefd LLC now owns 1,338 shares of the company’s stock valued at $165,000 after purchasing an additional 1,000 shares during the period. Finally, Financial Architects Inc boosted its holdings in shares of Neurocrine Biosciences by 283.7% in the third quarter. Financial Architects Inc now owns 1,385 shares of the company’s stock valued at $170,000 after purchasing an additional 1,024 shares during the period.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease.
Recommended Story: Market Capitalization – What it Means for Investors
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.